Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carl Zeiss Meditec AGXBUL:AFX 82 Cyclically Adjusted PS Ratio is 1.88 as of Aug. 13, 2026, which is 70% below its 10-year median of 6.23. GuruFocus rates XBUL:AFX with a GF Score™ of 82/100 and a GF Value™ of лв104.64. The stock has 4 warning signs investors should review. Among 526 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks better than 62.93% on this metric.
The historical rank and industry rank for Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio or its related term are showing as below:
XBUL:AFX'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.1 Med: 6.23 Max: 13.68
Current: 1.4
During the past years, Carl Zeiss Meditec AG's highest Cyclically Adjusted PS Ratio was 13.68. The lowest was 1.10. And the median was 6.23.
XBUL:AFX's Cyclically Adjusted PS Ratio is ranked better than 62.93% of 526
companies
in the Medical Devices & Instruments industry
Industry Median: 2.305
vs XBUL:AFX: 1.40
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Carl Zeiss Meditec AG's adjusted revenue per share data for the three months ended in Dec. 2025 was лв11.366. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is лв22.56 for the trailing ten years ended in Dec. 2025.
Shiller PE for Stocks: The True Measure of Stock Valuation
Carl Zeiss Meditec AG (XBUL:AFX) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Carl Zeiss Meditec AG Cyclically Adjusted PS Ratio Related Terms
Carl Zeiss Meditec AG Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carl Zeiss Meditec AG Cyclically Adjusted PS Ratio Chart
XBUL:AFX vs ISRG, BDX, MDLN: Cyclically Adjusted PS Ratio Comparison
For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carl Zeiss Meditec AG Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio falls into.
Carl Zeiss Meditec AG Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 1.88 mean?
Carl Zeiss Meditec AG (XBUL:AFX) has a Cyclically Adjusted PS Ratio of 1.88 as of Aug. 13, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Carl Zeiss Meditec AG and its competitors. This is 70% below median its historical median of 6.23. Over the past decade, Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio has ranged from 1.10 to 13.68. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #195 out of 526 companies in the Medical Devices & Instruments industry, placing it in the top 37.1%.
Is Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio too high?
Carl Zeiss Meditec AG's current Cyclically Adjusted PS Ratio of 1.88 is 70% below median its 10-year median of 6.23. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 13.68. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.31. Carl Zeiss Meditec AG's value of 1.88 is 18.4% below this industry median. Based on the distribution chart, Carl Zeiss Meditec AG ranks #195 out of 526 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Carl Zeiss Meditec AG has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #195 out of 526 companies for Cyclically Adjusted PS Ratio. This puts Carl Zeiss Meditec AG in the upper half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.31. Carl Zeiss Meditec AG's value of 1.88 is 18.4% below this benchmark. Historically, Carl Zeiss Meditec AG's own Cyclically Adjusted PS Ratio has ranged from 1.10 to 13.68 over the past decade. While the company's 10-year median is 6.23 vs. the industry median of 2.31, Carl Zeiss Meditec AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.31, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carl Zeiss Meditec AG's current Cyclically Adjusted PS Ratio of 1.88 is 18.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Carl Zeiss Meditec AG and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current Cyclically Adjusted PS Ratio is 1.88, which is 70% below median its own 10-year median of 6.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Carl Zeiss Meditec AG (XBUL:AFX) has a current Cyclically Adjusted PS Ratio of 1.88. The stock's GF Value™ is лв104.64, compared to a current price of лв42.34 — trading 59.5% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 1.88, which is 70% below median its 10-year median of 6.23 and 18.4% below the Medical Devices & Instruments industry median of 2.31. Carl Zeiss Meditec AG's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XBUL:AFX), the current Cyclically Adjusted PS Ratio is 1.88 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (XBUL:AFX) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of лв42.34 is trading 59.5% below its estimated GF Value™ of лв104.64.
Key valuation signals for XBUL:AFX:
Cyclically Adjusted PS Ratio: 1.88 (70% below median its 10-year median of 6.23)
GF Value™: лв104.64 vs. price of лв42.34 (59.5% below fair value)
Industry Position: 18.4% below the Medical Devices & Instruments median (#195 of 526)
No single metric tells the full story. See the XBUL:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
82GF Score
Get the complete analysis for XBUL:AFX
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:AFX has been successfully added to your 
